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Abstract
Harmonization of cancer variant representation, efficient communication, and free distribution
of clinical variant-associated knowledge are central problems that arise with increased usage of
clinical next-generation sequencing. The Clinical Genome Resource (ClinGen) Somatic Working
Group (WG) developed a minimal variant level data (MVLD) representation of cancer variants,
and has an ongoing collaboration with Clinical Interpretations of Variants in Cancer (CIViC), an
open-source platform supporting crowdsourced and expert-moderated cancer variant curation.
Harmonization between MVLD and CIViC variant formats was assessed by formal field-by-field
analysis. Adjustments to the CIViC format weremade to harmonize withMVLD and support Clin-
Gen Somatic WG curation activities, including four new features in CIViC: (1) introduction of an
assertions feature for clinical variant assessment following the Association ofMolecular Patholo-
gists (AMP) guidelines, (2) group-level curation tracking for organizations, enablingmember trans-
parency, and curation effort summaries, (3) introduction of ClinGen Allele Registry IDs to CIViC,
and (4) mapping of CIViC assertions into ClinVar submission with automated submissions. A gen-
eralizableworkflowutilizingMVLDandnewCIViC features is outlined for use byClinGenSomatic
WG task teams for curation and submission to ClinVar, and provides a model for promoting har-
monization of cancer variant representation and efficient distribution of this information.
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1 INTRODUCTION
Whole genome sequencing of the first cancer genome and subse-
quent efforts to survey the pan-cancer mutational landscape greatly
expanded the potential use of cancer variants for research, drug devel-
opment, and clinical applications (Hudson et al., 2010; Ley et al.,
2008; Weinstein et al., 2013). Clinical application of Next Generation
Sequencing (NGS) has enhanced molecular profiling capacity (Kamps
et al., 2017). NGS sequencingmethods are now commonly used in per-
sonalized clinical cancer care (Chang et al., 2017; Green et al., 2016).
However, NGS also yields increasing numbers of variants that pre-
dominantly are of unknown significance and compounds the challenge
of variant interpretation (Good, Ainscough, McMichael, Su, & Grif-
fith, 2014; Kamps et al., 2017). As clinical analysis of large volumes
of patient variant data becomes increasingly difficult, inconsistencies
increase both in variant interpretation and reporting between labora-
tories (Harrison et al., 2017). This issue is compounded by propagation
of these inconsistencies to widely accessed knowledgebases (Hoskin-
son, Dubuc, &Mason-Suares, 2017; Yorczyk, Robinson, & Ross, 2015).
This underscores the need for regularized clinical classification and
representation, as well as open distribution of standardized somatic
cancer variant knowledge (Amendola et al., 2015; Shah & Nathanson,
2017).
In order to create consistency and transparency in somatic vari-
ant interpretation, the Association of Molecular Pathology (AMP)
has recently published a set of guidelines for somatic variant inter-
pretation in cancer, which is seeing steady adoption across multiple
platforms (Li et al., 2017). However, currently the field of somatic
cancer variant classification is still in development, especially when
compared to variant interpretation for germline or Mendelian dis-
orders (Richards et al., 2008; Richards et al., 2015). Besides the
AMP cancer variant interpretation guidelines, there have been sev-
eral other proposed systems for somatic cancer variant classification,
which focus on variant therapeutic value (actionability), broader clini-
cal value, or use more complex bioinformatic approaches to the prob-
lem (Hoskinson et al., 2017; Sukhai et al., 2016; Van Allen et al., 2014).
Minimum variant level data (MVLD; described below and in reference)
was developed by The Clinical Genome Resource (ClinGen) Somatic
WG (WG) to provide a consensus-based, lightweight, andmodular for-
mat to transfer somatic variant data of clinical relevance (Ritter et al.,
2016). ClinGen is a global National Institutes of Health (NIH)-funded
effort to standardize gene and variant curation, for clinically relevant
genetic information, aiding in rapid communication of this informa-
tion between multiple end users including clinicians, research scien-
tists, and the public. ClinGen works closely with ClinVar, a database of
clinically relevant germline and somatic variants, to implement best-
practices in variant curation and presentation (Landrum et al., 2016a).
The SomaticWorkingGroup (WG) is in theClinical Domain of ClinGen,
and is composed of over 50 academic and industry stakeholders in can-
cer research.
Following development of MVLD to harmonize cancer variant
somatic data, the Somatic WG has focused on curation efforts
described below using the Clinical Interpretations of Variants in
F IGURE 1 Workflow for Clinical Genome Resource (ClinGen)
minimum variant level data (MVLD) formatted somatic cancer variant
submission to ClinVar utilizing the Clinical Interpretations of Variants
in Cancer (CIViC) assertion. MVLD formatted variant data is used by
ClinGen curators tomanually generate evidence items using CIViC
interface. ClinGen and CIViC curators and editors collaboratively use
this evidence to generate CIViC assertions. Assertions are submitted
to ClinVar via an automated program
Cancer web resource (CIViC—www.civicdb.org) as a curation platform
(Griffith et al., 2017). CIViC is a free, fully open access knowledgebase
and curation interface for cancer variants that may potentially impact
the clinical evaluation of a cancer patient. The knowledgebase uses
a crowdsourcing approach combined with expert curators from
organizations such as ClinGen (Expert Panels) and CIViC-trained
editors tomaintain and expand a resource for clinical interpretation of
variants. This addresses a critical need by assisting genome scientists
in evaluating the large volume of relevant variant data produced by
contemporary tumor NGS analysis (Good et al., 2014). CIViC is a
knowledgebase, which is currently NIH-funded, and provides data
with no license restrictions or costs to contribute, use, or view.
This work reports on a collaborative effort between the ClinGen
SomaticWGandCIViC team to employMVLDandnew features devel-
oped in the CIViC database for cross-platform curation of somatic
cancer variants and downstream automated submission to ClinVar
(Figure 1). Here we describe harmonizing the CIViC somatic variant
representation with that of MVLD, and offer a curation workflow for
somatic cancer variants that aligns the MVLD representation with
the CIViC somatic assertion format. Further, we have automated the
transformation of CIViC somatic assertions into ClinVar submissions
for consumption by the broader biomedical research community, and
provide the code, via GitHub, that enables this transformation to the
broader community as well. Our ultimate goal is to use data elements
developed through working with curation structures like MVLD and
platforms like CIViC to inform the streamlining and standardization
of cancer curation data in electronic medical records (EMR), combined
with other efforts in this area, such as HL7 Fast Healthcare Inter-
operability Resource (FHIR) and the GA4GH Genomic Knowledge
Standards (GKS) Variant Annotation Task Team (Khalilia et al., 2015;
Lawler et al., 2015).
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F IGURE 2 Overview of the relation of minimum variant level data (MVLD) structure to CIViC. Themajority ofMVLDAllele Descriptive and
Interpretive fields map to Clinical Interpretations of Variants in Cancer (CIViC) variant fields, whereasMVLD Somatic Interpretive fields are all
associated with CIViC evidence fields, which contain clinical interpretive information for the variant
2 MATERIALS AND METHODS
2.1 MVLD brief description
Briefly, MVLD is a metadata structure that guides selection of ontolo-
gies and terminologies (Ritter et al., 2016). MVLD organizes data ele-
ments into three categories: AlleleDescriptive, Allele Interpretive, and
Somatic Interpretive (Figure 2). The Allele Descriptive fields describe
the genomic identifiers of a variant: genome build, gene name, chro-
mosome, DNA position, and RefSeq transcript and protein. The Allele
Interpretive fields contain data that helps to understand the likely
effect and associated relevant literature identifiers (e.g., PubMed IDs).
The Somatic Interpretive fields hold data that pertain to the somatic
and clinical relevance of a variant. These fields are as follows: Can-
cer Type, Biomarker Class, Therapeutic Context, Effect, Level of Evi-
dence, and Sub-Level of Evidence. For a somatic variant, the Level
of Evidence captures the interpretation framework used for variant
assessment and is conceptually similar to the “assertion criteria” in
ClinVar. Although initially published with an example in the Level of
Evidence field from the Cancer Driver Log (CanDL), the MVLD has
been updated and adopted the interpretive tiers from the AMP guide-
lines (Damodaran et al., 2015; Li et al., 2017). It is important to note
that many somatic variant interpretive schemata could be recorded in
the Level of Evidence field (Parsons et al., 2016). Additionally, at the
current time, MVLD is tailored for somatic single nucleotide variants
(SNVs) and small insertion and deletion (indel) variants, with the inten-
tion to expand for relevant somatic events, such as RNA fusions, gene
amplifications, and chromosomal rearrangements.
2.2 CuratingMVLD formatted variants in CIViC:
Aworkflowmethod
The CIViC interface is used for variant curation and the creation
of variant assertions. The interface enables not only submission of
content, but also editing, approval, and discussion regarding changes
between curators and editors. Furthermore, it provides tracking and
recording of all of these actions, allowing transparency of CIViC cura-
tions. In this proposed workflow, the CIViC interface is used to both
accept evidence entries from MVLD-formatted and precurated data
using general CIViC moderation protocols and to subsequently create
variant assertions. An assertion in CIViC is a curation structure built
fromevidence items (EIDs; structured clinical data extracted frompub-
lished articles) for a single variant. When the collection of evidence
reflects the state of the field, theAssociation ofMolecular Pathologists
(AMP) somatic variant interpretation is applied with appropriate Tier
and Level.
Although CIViC admits a broad range of gene-centered variant
types, including “bucket” variants such as any mutations within a spe-
cific gene or domain, MVLD curation intended for CIViC will focus
on SNV and small indel variants. Implementing MVLD with CIViC is
best accomplished by a workflow and user optimization, and is not yet
scoped for automated transformation of data, although we may yet
develop it further. Specifically, MVLD will function as a record of pre-
curation for the Somatic Assertion feature in CIViC in the following
workflow: (1) the Somatic WG biocuration team members will curate
variants in MVLD format and pull associated PubMed identifiers
(PMIDs) into an MVLD record, (2) the MVLD record can then be reas-
signed to curation team members to pull the PMIDs, review the arti-
cles in-depth, extract CIViC EIDs, and enter them into the interface,
(3) upon completion of a series of EID entries, a CIViC Somatic Asser-
tion can be created, and (4) the SomaticWGwill review and approve a
“final” assertion in CIViC.
2.3 HarmonizingMVLD and CIViC:
A field-to-field analysis
Although the workflow for MVLD-guided ClinGen curation into CIViC
(Figure 2) does not involve an automatedmapping ofMVLD-formatted
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somatic variant data, a field-by-fieldmapping analysis fromMVLD into
CIViCwas performed to gauge harmonization of the variant represen-
tations (Supporting Information Figure S1a–c). In fields where a nat-
ural mapping from MVLD to CIViC was not apparent, workarounds
were formalized while maintaining the intent of the respective fields
from each system. In cases where no workaround of this nature was
apparent, the discrepancy was noted and evaluated, and if deemed
important, changes to the CIViC variant format were suggested and
implemented. Fields in CIViC that were outside the scope of MVLD
were also noted, and assessed for their relevance toward variant har-
monization between the two representation formats.
2.4 Automated CIViC to ClinVarmapping
for submission
A formal mapping based on fields drawn from the assertion and vari-
ant subsections of CIViC was constructed (Supporting Information
Figure S2a–c), which describes the relationship between CIViC ele-
ments and the fields required for variant submission to ClinVar. An
object-oriented python package and command-line application was
developed to query theCIViCdatabase for assertions over theRESTful
API, then evaluate and assemble the relevant information for a Clin-
Var submission from the resultant JSON responses. The CIViC asser-
tion is then used to create the required fields for a ClinVar record.
Each record is written to a ClinVar-compliant submission form for
entry into the ClinVar system. This open-source application is hosted
on GitHub at https://github.com/griffithlab/civic2clinvar, under the
permissive MIT software license. The CIViC database model will be
updatedwith a feature to track and version ClinVar submissions.
3 RESULTS
3.1 CIViC development to support ClinGen
somatic curation
3.1.1 Somatic Assertions: AMP Tiers and levels
MVLD formatted variants contain AMP somatic variant interpretation
guidelines as one of their central fields in the “Level of Evidence” ele-
ment (Li et al., 2017; Ritter et al., 2016). AMP somatic variant inter-
pretation guidelines assign a Tier and Level to classify a somatic vari-
ant. The AMP Tier and Level comprise a state of the field evaluation
and take into account all clinically relevant knowledge about a somatic
cancer variant in a given disease context. In contrast, the CIViC EID
is a granular unit of predictive, diagnostic, prognostic, or predispos-
ing evidence drawn from the literature. In order to support a sum-
mary statement about the clinically relevant knowledge for a given
cancer variant in CIViC, the Assertion feature was created. To support
a new first-class entity with complete functionality (e.g., commenting,
editing), changes to the underlying CIViC database and user interface
were made. Novel connections and tables were added to the database
schema to support Assertions with API endpoints to support multi-
ple web interface features. New advanced search parameters, naviga-
tion pages, help documents, and curation formswere added to the user
interface in addition to the complex EID searching and linking required
to generate an evidence-supported assertion. When the number and
quality ofCIViCEIDs of a certainCIViC somatic EvidenceType (predic-
tive, prognostic, or diagnostic) is deemed sufficient to reflect the state
of knowledge in the literature, then a curator may write an Assertion
(Figure 3), which summarizes the state of the field. Currently, the suf-
ficiency of evidence for an assertion is determinedmanually by assess-
ing the literature and EIDs; however, as more assertions are created,
analysis on contributing factors will help to automate and create stan-
dard operating procedures for identification of assertion-ready vari-
ants. Assertions require the curator to apply an appropriate AMP Tier
and Level, which in CIViC, range from Tier I Level A to Tier II Level D.
In CIViC, such an Assertion clearly links back to the data upon which
the Assertion is based, allowing for rapid integration and interpreta-
tion in the event of newly published results or the discovery of previ-
ously erroneously omitted data.
3.1.2 Organizations feature tracks curation progress
and ClinVar attributions at a group level
As CIViC has engaged in more collaborations at the organizational
level, a feature to group users into organizations was introduced into
the interface (Figure 4a). Every registered CIViC member may belong
to one organization, or have no organizational affiliation. An organiza-
tion page is provided, which features an organization description and
list of members (Figure 4b), along with organizational statistics detail-
ing multiple types of curation activity totals and a list of specific cura-
tion actions performed by the organization, as well as a list of all EIDs
submitted by organization members (Figure 4c). An organization for
ClinGen Somatic WGmembers was made in CIViC (Figure 4a–c), pro-
viding proper attribution for this group's efforts throughout the inter-
face and annotating the contributed records for submission to ClinVar
using the automated submission process described below. All Somatic
Assertions in CIViC will be submitted to ClinVar, and those that have
been reviewed by the Somatic WG task teams will be noted as such in
the ClinVar submission.
3.1.3 Utilizing ClinGen allele registry in CIViC
ClinGen Allele Registry provides unique and dereferenceable identi-
fiers for every registered variant (https://reg.clinicalgenome.org, and
see Patel et al in this issue). In addition, the Allele Registry generates
mapping to various genome assemblies and transcripts using Human
Genome Variation Society (HGVS) nomenclature. Coordinate descrip-
tions provided with each variant in CIViC are used to find identifiers
from the ClinGen Allele Registry (CAIds) using REST-APIs. Provided
identifiers are then used to generate click-through links at the CIViC
variant level and Assertion pages (Figure 5a and 5b). In the future, we
will also utilize the registration services to automate the registration of
new alleles if the variant of interest is not already present in the Allele
Registry.
3.1.4 Mapping CIViC to ClinVar for variant submission
Using fields made available with the addition of the Assertion fea-
ture, we have built a formal procedure for mapping CIViC fields into
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F IGURE 3 The Clinical Interpretations of Variants in Cancer (CIViC) assertion feature. The new assertion feature collects multiple evidence
items and summarizes them into an assertion statement. Variant details are given as well as a list of the evidence items used to construct the
assertion with Association ofMolecular Pathologists (AMP) Tier and Level
ClinVar submission fields for SNV and indel, along with a python tool
for implementing this formalism (Figure 6). This tool is easily expanded
to a wider array of variant types. The mapping from CIViC to ClinVar
fields is implementedwith three types of data: CIViC variant field data,
CIViC assertion field data, and procedurally generated entries into the
ClinVar sheet. CIViC variant fields map into ClinVar submission fields
with no alterations (Supporting Information Figure S2a). CIViC asser-
tion fields map into ClinVar fields with two fields (Condition ID Type
and Condition ID Value) requiring some additional logic to properly
format the entry (Supporting Information Figure S2b). Finally, there
are a set of ClinVar submission fields that require procedural genera-
tion based on logic that depends on the CIViC submission fields. These
fields along with the logic required for generating them are detailed in
the Supporting Information Figure S2c. An example of the output of
this procedure using a specific assertion (AID5 from Figure 3) is also
shown in the Supporting Information Figure S3).
3.2 Harmonizing and relatingMVLD to CIViC
for streamlined curation
In order to assess harmonization between the MVLD and CIViC-
formatted somatic variant, we performed a field-by-field mapping of
MVLD into CIViC after completion of the CIViC Somatic Assertions
update, and analyzed which fields map fromMVLD to CIViC in a natu-
ral way, which fields require workarounds to map, and which fields did
not admit a workaround for mapping. The latter fields in CIViC were
analyzed and suggested changes to CIViCwere proposed.
3.2.1 MappableMVLD to CIViC fields
Because MVLD was implemented as a modular, minimal data struc-
ture, and as CIViC and MVLD have an ongoing collaboration, CIViC
has already adopted some standards that are suggested in MVLD and
in common use by many variant curation databases, such as the use
of HGVS nomenclature. A review of the MVLD fields shows that all
six MVLD allele descriptive fields map cleanly into CIViC (Support-
ing Information Figure S1a). From the MVLD allele interpretive fields,
DNASubandPosition, Protein SubandPosition, VariantConsequence,
and PMIDs have close analogs in CIViC (Supporting Information
Figure S1b). Among the MVLD somatic interpretive fields, all fields
map except for Biomarker Class and the expert opinion Sub-Level of
Evidence (Supporting Information Figure S1c), which are discussed
below.
3.2.2 RelatableMVLD to CIViC fields
Some fields do not map from MVLD to CIViC in a direct fashion, but
admit a relation or adaption to the mapping that does not require
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F IGURE 4 Clinical Interpretations of Variants in Cancer (CIViC) organizations page. The CIViC organizations feature is displayed on the
community page of theweb interface (https://civicdb.org/community/organizations). (a) Each organization icon serves as a link to an organization's
page. (b) The organization's page gives a brief description of the organization and lists CIViC curators and editors that aremembers. (c) Detailed
statistics for the organization are provided as well as a summary of organization CIViC activity. A downloadable list of CIViC evidence items
submitted by the organization is also provided
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F IGURE 4 Continued
changes to the variant format of eitherMVLD or CIViC. One such field
is the MVLD conception of Somatic Classification, which requires that
a variant be confirmed somatic or germline, which requires matched
tumor and normal control sequencing for confirmation. CIViC does
not require matched normal for cases where there is a strong rea-
son to make the assumption that the variant is somatic, as is the
case in many cancer studies that do not perform this verification. In
cases where somatic origin is less clear, CIViC uses the termUnknown.
To work around this difference, ClinGen SWG curators will provide
details on control sequencing in the CIViC Evidence Statement. This
level of experimental detail is already often voluntarily employed by
CIViC curators. Although the MVLD Variant Type has no direct ana-
log in CIViC, the MVLD Variant Consequence naturally maps to the
CIViC Variant Type field, which is drawn from the Sequence Ontology
(Eilbeck et al., 2005). AnotherMVLD field that does notmap intoCIViC
is the Expert Opinion Sub-Level of Evidence (Supporting Information
Figure S1c). As CIViC relies exclusively on primary published data doc-
umented with a PMID, expert opinion has no analog in the CIViC data
model. This is addressed by curation workflow handling of PMIDs,
outlined below.
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F IGURE 5 Clinical GenomeResource (ClinGen) Allele Registry in the Clinical Interpretations of Variants in Cancer (CIViC) interface. (a) A link to
the ClinGen Allele Registry has been added to the CIViC variant page. For single nucleotide variants (SNVs) and small insertions and deletions, the
ClinGen allele is identified automatically once CIViC variant coordinates are curated. (b) ClinGen Allele Registry page for a SNV type variant
3.2.3 NonrelatableMVLD to CIViC fields
and implemented CIViCmodifications
Other fields in MVLD do not admit a mapping into CIViC, and also did
not admit a workflow modification to handle this incongruence. One
such set of fields are MVLD's Somatic Interpretive Effect fields that
are adopted from Dienstmann, and consist of five levels as follows:
Resistant, Responsive, Not-Responsive, Sensitive, and Reduced
Sensitivity (Dienstmann et al., 2014). In CIViC, the Effect fields are
mainly used for the Predictive biomarker class, as opposed to the
Diagnostic and Prognostic classes, whereas in MVLD, the Effect field
is optional and may be used for prognostic class. In the CIViC EID
and Somatic Assertion, data comparable to the MVLD Effect field are
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F IGURE 6 Overview of automated ClinVar submission procedure.
The ClinVar submission tool distinguishes three types of fields in the
ClinVar submission form: those that accept Clinical Interpretations of
Variants in Cancer (CIViC) assertion fields, those that accept CIViC
variant fields, and those that require procedural generation to
determine the field value
contained by two metadata fields—the Evidence Direction and
Clinical Significance—that are paired to the Evidence Type (MVLD
Biomarker Class). CIViC's Evidence Direction and Clinical Significance
do not cover all of the Effect fields employed by MVLD adopted from
Dienstmann et al. (2014). In order to capture these fields, CIViC has
implemented changes to the Clinical Significance fields (Figure 7a).
The term Sensitivity is changed to Sensitivity/Response, and the term
Resistance or Non-Response is changed to Resistance. Also, the term
Reduced Sensitivity is added to the CIViC fields. With these changes
in place, a mapping of the five terms adopted from Dienstmann is
available in CIViC (Figure 7b), with the exception that the Dienstmann
terms Sensitive and Responsive have been reduced to the single com-
pound term Sensitivity/Response in CIViC. We note that in all cases,
further nuances to categories can be added to text in the Evidence
Statement.
3.2.4 Comparison ofMVLD and CIViC handling of
PubMed IDs
Although in an MVLD representation of a somatic variant, the PMID
fields are optional to allow for unpublished case data, it is recom-
mended and required in the proposed curation workflow that the
PMIDs constitute support for the AMP somatic variant interpretation
assigned to the MVLD variant. The collection of PMIDs in an MVLD
record forms the evidence sufficient to support the AMP somatic vari-
ant interpretation. In contrast, CIViC relies upon individuated EIDs for
a variant. It is not required in CIViC that a variant's collection of EIDs
is representative of the field. Instead, when the quantity and quality of
EIDs in CIViC reach the point of summarizing the state of the field for
a given variant and disease, then an assertion can be written for this
particular combination of variant and disease.
3.2.5 Required CIViC fields
Curation of diagnostic and prognostic evidence in CIViC requires an
evidence direction and Evidence Statement, whereas in MVLD, these
F IGURE 7 Updating Clinical Interpretations of Variants in Cancer (CIViC) clinical significance terms for harmonization with other standards. (a)
Sensitivity is expanded to indicate sensitivity and responsiveness, and resistance or Nonresponse is restricted to Resistance. The new term
Reduced Sensitivity adds gradation to Clinical Interpretations of Variants in Cancer (CIViC) evidence. (b)Mapping of the structure of minimum
variant level data (MVLD) terms adopted fromDienstmann onto updated CIViC terms
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fields are left as open text. This is solved via a guideline toMVLDprecu-
ration, which requires curators to assign evidence directionwhen deal-
ingwith diagnostic or prognosticMVLDBiomarker Classes. CIViC also
employs a star rating system for submitted evidence, which is a rating
of the quality of a unit of evidence submitted to CIViC—in the form of
an EID—which is drawn from a publication. ClinGen curators who have
read and assessed the evidence being submitted assign these ratings
upon submission in the CIViC interface.
3.3 Variant curation through somatic expert review
and ClinVar submissions
3.3.1 Variant curation standard operating procedure
and task teams
The Somatic WG has adopted much of the structure of ClinGen
GermlineExpertPanels for their curation task teams, and is formalizing
the process of Somatic Expert Panels. The Somatic WG is divided into
curation task teams focused on cancers and genes, including the fol-
lowing: Pediatric Somatic Cancers, Pancreatic Cancers, Nonsmall Cell
Lung Cancers, and Somatic TP53 Mutations. Each task team defines
team leaders and participants, a gene and variant set, a monthly meet-
ing agenda, and mission statement that includes curation targets with
the available workforce. In an initial round of curation prior to task
team formation, the Somatic WG added ∼80 EIDs to CIViC, from a
set of ∼30 high-impact cancer genes that lacked somatic assertions in
ClinVar. Following this, the task teamshaveeachestablished functional
curation plans. Here, we review the Pediatric Somatic Working Group
(PSWG) curation plan as an example. The PSWG has defined a set of
pediatric cancer genes in specific childhood tumor types, and has iden-
tified and prioritized variants in disease-gene pairs using Mastermind,
a literature mining search tool (https://mastermind.genomenon.com/).
A gene-disease search in Mastermind produces a list of variants, and
these are prioritized based on the following: (1) overall absence of
curated data in CIViC, (2) the number of article hits against the Mas-
termind search, (3) the number of hits against a PubMed search, and
(4) reviewof variants in pediatric-relevant datasets (Chakravarty et al.,
2017; Ma et al., 2018). The variants are discussed and vetted with
experts on the WG call. After an initial round of curation, curators
assemble theMVLD record from a high-level literature review and pull
in relevant articles. In this step, experts in theWGmay be familiar with
relevant articles and list them in addition to articles listed in theMVLD
record. The MVLD can then be assigned to trainees and onboarding
curators to extract EIDs from the PMIDs and assemble into a Somatic
Assertion. The Pediatric Task Team reviews the Somatic Assertions on
monthly calls and provides feedback on curation and interpretation of
the EIDs.
3.3.2 SomaticWGmoderation in CIViC
Currently, CIViC editors moderate ClinGen Somatic WG submissions.
Moderation requires a curatorwitheditor-level status to review the lit-
erature used to create an EID, after which an editor can directly accept
the submission, or if deemed necessary, revise the entry by suggest-
ing revisions. Members of the Somatic WG who specialize in somatic
biocuration will receive “editor-level” status to moderate submissions
from the ClinGen SomaticWG.
3.3.3 SomaticWG curation and submission to ClinVar
After ClinVar submission of a small test set of somatic assertions, a
larger set of 500 submissions is expected to be completed by end of
2018. As part of an ongoing effort, CIViC will submit all assertions to
ClinVar on a biannual basis. Aswe further develop and solidify the sub-
mission process and as the rate of assertions in CIViC increases, we
may seek to increase the number of submissions. Assertions generated
by ClinGen SomaticWGwill use the CIViC organization's functionality
to be labeled as such for ClinVar submission.
4 DISCUSSION
With the publication of the AMP Somatic Variant Interpretation
Guidelines and implementation of the Somatic Assertion (Tier and
Level) into CIViC, a close homology was attained in the MVLD and
CIViC representations of somatic cancer variants. Granular field map-
ping revealed many points of practical agreement between CIViC and
MVLD data models, requiring relatively minor modifications to CIViC.
Combining the efforts of the ClinGen Somatic WG and CIViC somatic
variant interpretation models into a practical curation workflow pro-
vides a strong basis for reporting, discussing, and curating the most
clinically-relevant somatic variants in a consensus building and flexi-
ble structure that will allow for updates as somatic variant guidelines
evolve. Ideally, the detailed provenance of this effort will influence
upcoming somatic variant guidelines.
The increasing amount of somatic variants produced by clin-
ical sequencing necessitates rapid curation and dissemination.
Currently, there are multiple platforms and portals hosting cancer
variant data with a clinical focus, including OncoKB, CanDL, My Can-
cer Genome, The Jackson Laboratories Clinical Knowledgebase, and
ClinVar (Chakravarty et al., 2017; Damodaran et al., 2015; Landrum
et al., 2016b; Patterson et al., 2016; Swanton, 2012). This speaks to the
need for coordinated efforts such as that presented here to define and
relate central data elements. We hope to extend the interoperability
further to additional curation platforms. It is relevant here that the
way the community shares clinically identified variants is also rapidly
evolving.Many journals, such asMolecular Case Studies, NPJ Genomic
Medicine, Human Genome Variation, and JCO Precision Oncology,
are beginning to accept cancer genetics case studies as a new pub-
lication format. These provide a vehicle and a rapid mechanism to
share molecular analysis of patients or cohorts alongside their clinical
phenotypic information. These n-of-1 reports are short standardized
reports about genomic variation and variability, especially in relation
to a disease or drug sensitivity or resistance. However, many jour-
nals require submission of variants or sequencing results to public
databases in order to promote data sharing. Databases that rely on
PMIDs and literature variant curation may not accept relevant cancer
cases due to lack of publication evidence. Cancer Genetics will soon
implement a new rapid publicationmodel thatwill highlight interesting
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cancer cases and associated variants, with the intention that variant
data would be submitted to the journal in MVLD format followed
by submission and curation in CIViC after PMID assignment. Cancer
medicine will greatly benefit from the large scale dissemination of this
case-based knowledge to a wide community. In addition, precision
oncology could be substantially improved from the biocuration and
systematic reviews communities coming together, given the emphasis
of the former on timely knowledge dissemination and the latter
on systematic assessment of the literature and the risk of bias. For
example, curated databases like CIViC could be considered as one
of the inputs to systematic reviews while at the same time always
including outputs from systematic reviews (Boca, Panagiotou, Rao,
McGarvey, & Madhavan, 2018). The MVLD–CIViC effort outlined
here provides a framework to solve these problems, employing MVLD
format standardization and CIViC's commitment to ensure no barriers
exist for those seeking access to these findings.
Efforts such as the one presented here demonstrate the utility of
MVLD as a central structuring principle for variant representation,
which can streamline somatic variant curation, and make lateral trans-
fer of variant knowledge more efficient and rapid as a standardized
conception for a somatic cancer variant emerges. Such a framework
not only allows for standardization but also allows for integration of
data generated by different laboratories to enable novel hypothesis
generation for precision oncology. Likewise, commitment to an open
data model such as that adhered to by CIViC is essential to enabling
this process, which in turn serves tominimize redundant effort in tack-
ling the enormous problem of cancer somatic variant curation and
interpretation. Efficient distribution of information, including map-
pings and automations such as those presented here, further enables
rapid adoption of new findings to clinical applications such as panels, or
drug development, and standardizations enablemore efficient integra-
tion, with minimal redundancy, of updated variant interpretations into
tools such as EMR. Although a data warehouse, such as ClinVar, could
store and serve variant curation data, it is abundantly clear that mul-
tiple curation input platforms are preferred by biocurators and those
contributing curations, and thus establishing shared core elements is
essential to the development and design of curation platforms. Cura-
tion effort as awhole is obviously crucial to the success of these efforts,
and part of this effort may be incentivized in the form of training the
next generation of cancer data scientists, as the curator interested in
understanding the current state of the field greatly benefits from these
activities.
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